Found "Medical Procedures": 262 results
Sort by
Relevance

HTA WORKSHOP AT THE JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH (JIPMER)

The Health Intervention and Technology Assessment Program (HITAP) has supported the development of Health Technology Assessment (HTA) in India by building technical capacity and knowledge through collaborations with several academic institutions in India on HTA. HITAP recently partnered with the Jaw

NICE International Review 2015

INTRODUCTION TO THE YEAR’S EVENTS 2015 was our best year yet – a year that saw our international Decision Support Initiative (iDSI) grow from a fledgling enterprise to a trusted source of knowledge and support for those setting healthcare priorities. With our iDSI partners in Thailand (HITAP),

Evidence-based decision-making in Asia-Pacific with rapidly changing health-care systems: Thailand, South Korea, and Taiwan. (2009)

Evidence-Based Decision-Making in Asia-Pacific with Rapidly Changing Health-Care Systems: Thailand, South Korea, and Taiwan. Thidaporn Jirawattanapisal1 Pritaporn Kingkaew2 Tae-Jin Lee3 Ming-Chin Yang4 1International Health Policy Program, Ministry of Public Health, Muang Nonthaburi,Thailand; 2

Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment. (2010)

Criteria for priority setting of HIV/AIDS interventions in Thailand: a discrete choice experiment Sitaporn Youngkong*1,2, Rob Baltussen*1, Sripen Tantivess*2, Xander Koolman*3 and Yot Teerawattananon*2 1 Nijmegen International Center for Health Systems Research and Education (NICHE), Department of

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand (2013)

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

A Cost-Utility Analysis Comparing Standard Axillary Lymph Node Dissection with Sentinel Lymph Node Biopsy in Patients with Early Stage Breast Cancer in Thailand (2014)

Abstract Objectives In Thailand, axillary lymph node dissection (ALND) is the dominant form of treatment for breast cancer, even though the treatment often leaves patients with some degree of arm morbidity. Sentinel lymph node biopsy (SNB) is widely accepted globally as a preferable alternative pr

A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand (2014)

Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I

Cost-utility analysis of great saphenous vein ablation with radiofrequency, foam and surgery in the emerging health-care setting of Thailand (2015)

Boonying Siribumrungwong1, Pinit Noorit2, Chumpon Wilasrusmee3, Pattara Leelahavarong4, Ammarin Thakkinstian5 and Yot Teerawattananon4 Abstract Objectives: To conduct economic evaluations of radiofrequency ablation, ultrasound-guided foam sclerotherapy and surgery for great saphenous vein ab

Vaccination program in a resource-limited setting: A case study in the Philippines

Objective: Implementing national-level vaccination programs involves long-term investment, which can be a significant financial burden, particularly in resource-limited settings. Although many studies have assessed the economic impacts of providing vaccinations, evidence on the positive and negative

Economic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis
10 / Page